Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.48p
   
  • Change Today:
    -0.025p
  • 52 Week High: 4.00
  • 52 Week Low: 0.42
  • Currency: UK Pounds
  • Shares Issued: 374.35m
  • Volume: 1,283,279
  • Market Cap: £1.78m
  • RiskGrade: 435
  • Beta: 0.04

Deal with Barclays    Trade now with Barclays Stockbrokers

Valirx Overview

ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -22990.0% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 187.2 n/a
Pr/Book 0.6  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Valirx Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 n/a (2.72) (4,135.00)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (1.54) (3.81)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (1.68) (2.34)p n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (2.60) (3.06)p n/a n/a n/a n/a 0.0%
31-Dec-23 0.01 (2.30) (2.01)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Valirx Company Announcements

Termination of Letter of Intent with TheoremRx 03-Apr-2025 07:00 RNS
Directorate Changes and new Advisory Board 27-Mar-2025 07:00 RNS
Director Disclosure Update 21-Mar-2025 11:07 RNS

Valirx ShareCast News

ValiRx terminates exclusive negotiations with Th... 03-Apr-2025 ShareCast
ValiRx's Inaphaea inks deal with UK-based Screen... 03-Feb-2025 ShareCast
ValiRx enters evaluation and option deal with Ca... 29-Jan-2025 ShareCast

Valirx Top Newspaper Links

Business Digest 24-Sep-2006 Sunday Times

Latest Valirx Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Valirx Market Data

Currency UK Pounds
Share Price 0.48p
Change Today -0.025p
% Change -5.00 %
52 Week High 4.00
52 Week Low 0.42
Volume 1,283,279
Shares Issued 374.35m
Market Cap £1.78m
Beta 0.04
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
21.99% above the market average21.99% above the market average21.99% above the market average21.99% above the market average21.99% above the market average
27.66% above the sector average27.66% above the sector average27.66% above the sector average27.66% above the sector average27.66% above the sector average
Price Trend
98.01% below the market average98.01% below the market average98.01% below the market average98.01% below the market average98.01% below the market average
95.83% below the sector average95.83% below the sector average95.83% below the sector average95.83% below the sector average95.83% below the sector average
Income Not Available
Growth Not Available

Valirx Dividends

No dividends found

Trades for 28-Apr-2025

Time Volume / Share Price
12:22 100,000 @ 0.48p
12:22 324,397 @ 0.45p
11:02 587,074 @ 0.49p
10:18 51,000 @ 0.51p
10:03 80,103 @ 0.49p

Valirx Key Personnel

CFO Gerald Desler

Top of Page